An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.
William Lobb
Advertisement
VP-Strategic Initiatives, PRMA (pricing, reimbursement and market access), Indegene
Articles by William Lobb
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Announces Major Shake Ups to Board
2
Merck Planning $70 Billion Investment for US Expansion
3
Shifting Focus in Autoimmune Diseases
4
FDA Accepts Tzield for Expedited Review Under The Commissioner’s National Priority Voucher Program
5
